Publication Type
Journal Article
Version
publishedVersion
Publication Date
7-1994
Abstract
Current therapy can induce a long-term remission in half the patients with diffuse lymphomas with a large-cell component (DLLC), but more intensive treatment has the potential to improve outcome. Rearrangement of a novel candidate proto-oncogene, bcl-6, correlates with a favorable clinical outcome in DLLC and may thus serve as a prognostic marker.
Discipline
Econometrics | Medicine and Health Sciences
Research Areas
Econometrics
Publication
New England Journal of Medicine
Volume
331
Issue
2
First Page
74
Last Page
80
ISSN
0028-4793
Identifier
10.1056/NEJM199407143310202
Publisher
Massachusetts Medical Society
Citation
Offit, K.; Louie, D.C.; Parsa, N. Z.; Leung, Denis H. Y.; Portlock, C.; Ye, B.H.; Lista, F.; Filippa, D.A.; Rosenbaum, A.; Ladanyi, M.; Jhanwar, S.; Dalla-Favera, R.; and Changanti, R.S.K..
Rearrangement of the Bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma. (1994). New England Journal of Medicine. 331, (2), 74-80.
Available at: https://ink.library.smu.edu.sg/soe_research/92
Copyright Owner and License
Publisher
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Additional URL
https://doi.org/10.1056/NEJM199407143310202
